PL2976359T5 - Sposoby leczenia wrodzonej łamliwości kości - Google Patents
Sposoby leczenia wrodzonej łamliwości kościInfo
- Publication number
- PL2976359T5 PL2976359T5 PL14717386.8T PL14717386T PL2976359T5 PL 2976359 T5 PL2976359 T5 PL 2976359T5 PL 14717386 T PL14717386 T PL 14717386T PL 2976359 T5 PL2976359 T5 PL 2976359T5
- Authority
- PL
- Poland
- Prior art keywords
- methods
- osteogenesis imperfecta
- treating osteogenesis
- treating
- imperfecta
- Prior art date
Links
- 206010031243 Osteogenesis imperfecta Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361803647P | 2013-03-20 | 2013-03-20 | |
| US201361875399P | 2013-09-09 | 2013-09-09 | |
| US201361883151P | 2013-09-26 | 2013-09-26 | |
| EP14717386.8A EP2976359B2 (en) | 2013-03-20 | 2014-03-20 | Methods for treating osteogenesis imperfecta |
| PCT/US2014/031279 WO2014153435A1 (en) | 2013-03-20 | 2014-03-20 | Methods for treating osteogenesis imperfecta |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL2976359T3 PL2976359T3 (pl) | 2019-03-29 |
| PL2976359T5 true PL2976359T5 (pl) | 2022-07-18 |
Family
ID=50483613
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14717386.8T PL2976359T5 (pl) | 2013-03-20 | 2014-03-20 | Sposoby leczenia wrodzonej łamliwości kości |
| PL17206987T PL3312195T3 (pl) | 2013-03-20 | 2014-03-20 | Sposoby leczenia wrodzonej łamliwości kości |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17206987T PL3312195T3 (pl) | 2013-03-20 | 2014-03-20 | Sposoby leczenia wrodzonej łamliwości kości |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US9598486B2 (pl) |
| EP (3) | EP3312195B1 (pl) |
| JP (3) | JP6483086B2 (pl) |
| KR (1) | KR102257138B1 (pl) |
| CN (2) | CN111000997A (pl) |
| AU (1) | AU2014235933B2 (pl) |
| CA (1) | CA2907422C (pl) |
| CL (1) | CL2015002801A1 (pl) |
| DK (2) | DK3312195T3 (pl) |
| EA (1) | EA032327B1 (pl) |
| ES (2) | ES2700238T5 (pl) |
| HR (2) | HRP20181939T4 (pl) |
| HU (1) | HUE046702T2 (pl) |
| IL (2) | IL241461B (pl) |
| LT (2) | LT2976359T (pl) |
| MX (2) | MX389759B (pl) |
| MY (1) | MY172324A (pl) |
| PH (2) | PH12015501864A1 (pl) |
| PL (2) | PL2976359T5 (pl) |
| PT (2) | PT2976359T (pl) |
| RS (2) | RS59673B1 (pl) |
| SG (2) | SG11201506683XA (pl) |
| SI (2) | SI2976359T2 (pl) |
| TW (1) | TWI629995B (pl) |
| UY (1) | UY35493A (pl) |
| WO (1) | WO2014153435A1 (pl) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2976359T5 (pl) * | 2013-03-20 | 2022-07-18 | Genzyme Corporation | Sposoby leczenia wrodzonej łamliwości kości |
| TWI726870B (zh) | 2015-03-04 | 2021-05-11 | 美商健臻公司 | 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體 |
| TWI733661B (zh) * | 2015-03-04 | 2021-07-21 | 美商健臻公司 | 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體 |
| AU2017310344A1 (en) * | 2016-08-11 | 2019-03-07 | Precithera, Inc. | TGF-β antagonist conjugates |
| CN106755395B (zh) * | 2016-12-16 | 2020-05-12 | 山东第一医科大学(山东省医学科学院) | Xi型成骨不全致病基因fkbp10的突变位点及其应用 |
| AR110904A1 (es) * | 2017-01-20 | 2019-05-15 | Sanofi Sa | ANTICUERPOS ANTI-TGF-b Y SU USO |
| TWI787230B (zh) * | 2017-01-20 | 2022-12-21 | 法商賽諾菲公司 | 抗ＴＧＦ-β抗體及其用途 |
| TW202421659A (zh) * | 2017-01-20 | 2024-06-01 | 美商健臻公司 | 骨靶向抗體 |
| EA201991729A1 (ru) * | 2017-01-20 | 2019-12-30 | Санофи | Антитела к tgf-бета и их применение |
| WO2019113123A1 (en) * | 2017-12-04 | 2019-06-13 | Precithera, Inc. | TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING |
| AU2019301283B2 (en) | 2018-07-10 | 2024-12-19 | Sanofi | Combination therapies against cancer targeting CD38 and TGF-beta |
| EA202092684A1 (ru) | 2018-08-27 | 2021-03-11 | Ридженерон Фармасьютикалз, Инк. | Применение рамановской спектроскопии для последующей очистки |
| CN110916855A (zh) * | 2018-09-20 | 2020-03-27 | 天津正天医疗器械有限公司 | 一种仿生多孔椎间植入物及其制造方法 |
| MX2023004725A (es) * | 2020-10-23 | 2024-02-23 | Hq Han | Antagonistas bifuncionales del factor de necrosis tumoral alfa y del factor de crecimiento transformante beta y usos de los mismos. |
| CA3219219A1 (en) * | 2021-05-07 | 2022-11-10 | Baylor College Of Medicine | Treatment of moderate-to-severe osteogenesis imperfecta |
| CN113501879B (zh) * | 2021-06-30 | 2022-09-06 | 拜盖特生物科技(上海)有限公司 | 一种解除肿瘤免疫微环境中免疫抑制的双功能抗体及其应用和制备方法 |
| TW202334209A (zh) * | 2021-11-01 | 2023-09-01 | 美商健臻公司 | 成骨不全症之治療 |
| AU2024207355A1 (en) * | 2023-01-13 | 2025-08-21 | Chimagen Biosciences, Ltd | Multi-specific polypeptide complexes |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL6716836A (pl) * | 1967-12-11 | 1969-06-13 | ||
| US7368111B2 (en) * | 1995-10-06 | 2008-05-06 | Cambridge Antibody Technology Limited | Human antibodies specific for TGFβ2 |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| US6416737B1 (en) * | 1998-11-19 | 2002-07-09 | Board Of Trustees Of The University Of Arkansas | Increasing bone strength with selected bisphosphonates |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| US6395511B1 (en) * | 1998-11-27 | 2002-05-28 | Darwin Discovery, Ltd. | Nucleic acids encoding a novel family of TGF-β binding proteins from humans |
| US6492497B1 (en) * | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
| CA2308532C (en) * | 1999-05-12 | 2005-11-29 | Gador S.A. | Use of bisphosphonates for the treatment of osteogenesis imperfecta |
| US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| ES2711213T3 (es) * | 2005-02-08 | 2019-04-30 | Genzyme Corp | Anticuerpos de TGFbeta |
| TW200714289A (en) * | 2005-02-28 | 2007-04-16 | Genentech Inc | Treatment of bone disorders |
| US7592429B2 (en) * | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| CA2632799A1 (en) | 2005-12-23 | 2007-07-05 | Eli Lilly And Company | Tgf-beta binding compositions |
| WO2008022182A1 (en) * | 2006-08-16 | 2008-02-21 | The Uab Research Foundation | Methods for promoting coupling between bone formation and resorption |
| TWI606062B (zh) | 2007-02-09 | 2017-11-21 | 艾瑟勒朗法瑪公司 | 包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途 |
| JP2010528586A (ja) * | 2007-04-26 | 2010-08-26 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 骨形成及び鉱化作用を調節する化合物の同定のためのアッセイ |
| TWI489993B (zh) * | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法 |
| EA201001162A1 (ru) * | 2008-01-15 | 2010-12-30 | Калобиос Фармасьютикалс, Инк. | Способы лечения расстройств с уменьшением костной массы с использованием антагониста gm-csf |
| US20120294868A1 (en) * | 2009-04-24 | 2012-11-22 | Edwards James R | Anti-tgf-beta induction of bone cell function and bone growth |
| PL2976359T5 (pl) * | 2013-03-20 | 2022-07-18 | Genzyme Corporation | Sposoby leczenia wrodzonej łamliwości kości |
-
2014
- 2014-03-20 PL PL14717386.8T patent/PL2976359T5/pl unknown
- 2014-03-20 PT PT14717386T patent/PT2976359T/pt unknown
- 2014-03-20 MY MYPI2015702733A patent/MY172324A/en unknown
- 2014-03-20 CA CA2907422A patent/CA2907422C/en active Active
- 2014-03-20 SI SI201430985T patent/SI2976359T2/sl unknown
- 2014-03-20 EP EP17206987.4A patent/EP3312195B1/en active Active
- 2014-03-20 AU AU2014235933A patent/AU2014235933B2/en active Active
- 2014-03-20 DK DK17206987.4T patent/DK3312195T3/da active
- 2014-03-20 PL PL17206987T patent/PL3312195T3/pl unknown
- 2014-03-20 CN CN201910988588.9A patent/CN111000997A/zh active Pending
- 2014-03-20 MX MX2019009122A patent/MX389759B/es unknown
- 2014-03-20 TW TW103110468A patent/TWI629995B/zh active
- 2014-03-20 RS RS20191624A patent/RS59673B1/sr unknown
- 2014-03-20 CN CN201480028990.8A patent/CN105229028B/zh active Active
- 2014-03-20 LT LTEP14717386.8T patent/LT2976359T/lt unknown
- 2014-03-20 JP JP2016504355A patent/JP6483086B2/ja active Active
- 2014-03-20 SI SI201431435T patent/SI3312195T1/sl unknown
- 2014-03-20 US US14/772,708 patent/US9598486B2/en active Active
- 2014-03-20 HU HUE17206987A patent/HUE046702T2/hu unknown
- 2014-03-20 WO PCT/US2014/031279 patent/WO2014153435A1/en not_active Ceased
- 2014-03-20 LT LTEP17206987.4T patent/LT3312195T/lt unknown
- 2014-03-20 UY UY0001035493A patent/UY35493A/es not_active Application Discontinuation
- 2014-03-20 EA EA201591843A patent/EA032327B1/ru not_active IP Right Cessation
- 2014-03-20 HR HRP20181939TT patent/HRP20181939T4/hr unknown
- 2014-03-20 ES ES14717386T patent/ES2700238T5/es active Active
- 2014-03-20 EP EP14717386.8A patent/EP2976359B2/en active Active
- 2014-03-20 SG SG11201506683XA patent/SG11201506683XA/en unknown
- 2014-03-20 RS RS20181438A patent/RS58188B2/sr unknown
- 2014-03-20 DK DK14717386.8T patent/DK2976359T4/da active
- 2014-03-20 MX MX2015013402A patent/MX369360B/es active IP Right Grant
- 2014-03-20 KR KR1020157028130A patent/KR102257138B1/ko active Active
- 2014-03-20 PT PT172069874T patent/PT3312195T/pt unknown
- 2014-03-20 EP EP19194235.8A patent/EP3640260A1/en active Pending
- 2014-03-20 ES ES17206987T patent/ES2763869T3/es active Active
- 2014-03-20 SG SG10201701985YA patent/SG10201701985YA/en unknown
-
2015
- 2015-08-25 PH PH12015501864A patent/PH12015501864A1/en unknown
- 2015-09-10 IL IL241461A patent/IL241461B/en unknown
- 2015-09-17 CL CL2015002801A patent/CL2015002801A1/es unknown
-
2017
- 2017-02-08 US US15/427,920 patent/US10377819B2/en active Active
-
2019
- 2019-02-06 PH PH12019500261A patent/PH12019500261B1/en unknown
- 2019-02-12 JP JP2019022397A patent/JP6677837B2/ja active Active
- 2019-07-01 US US16/459,023 patent/US11230595B2/en active Active
- 2019-12-17 HR HRP20192277TT patent/HRP20192277T1/hr unknown
-
2020
- 2020-03-12 JP JP2020042524A patent/JP7016113B2/ja active Active
-
2021
- 2021-11-08 IL IL287915A patent/IL287915A/en unknown
- 2021-12-09 US US17/547,069 patent/US12365725B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287915A (en) | Methods for treating brittle bones | |
| IL240713A0 (en) | Complexes for handling materials | |
| GB2513368B (en) | Process apparatus | |
| PL2983787T3 (pl) | Sposób leczenia zespołu stresu pourazowego | |
| SG11201603050TA (en) | Methods for treating cancers | |
| GB201318983D0 (en) | Radiotherapy apparatus | |
| IL243570A0 (en) | Combined treatment for atopic dermatitis | |
| AP2015008803A0 (en) | Methods for treating psoriasis using an anti-il-23antibody | |
| HUE042470T2 (hu) | Eljárás széntartalmú anyagok kezelésére gõz termolízissel | |
| IL245541A0 (en) | New methods for the treatment of neurodegenerative diseases | |
| PL3016682T3 (pl) | Sposoby leczenia nowotworu | |
| ZA201604486B (en) | Timber treatment process | |
| TWI563128B (en) | Methods for treating aluminum surfaces | |
| GB201603031D0 (en) | UV apparatus | |
| GB201322174D0 (en) | Process for treating steel components | |
| EP2985265A4 (en) | PROCESS FOR TREATING RESIDUAL WATER | |
| ZA201506163B (en) | Methods for treating osteogenesis imperfecta | |
| GB201322764D0 (en) | Treating places | |
| IL228606A0 (en) | Surface treatment process |